2008 - Factores de crecimiento hematopoyético-Dr. A. Biete - GICOR

Recommendations

Info

Tumor response Complete response: fixed effects Study Epoetin n/H Cascres 1994 Cazzola 1995 Cazzola 1995 Dammacco 2001 Littlewood 2001 Throuvalaz 2000 Ten Bokkel 1995 Ten Bokkel Osterborg 2002 Total (95% CI) Test for heterogeneity chi-square=10.97: a=8 p=0.2 Test for overall effect z=2.53 p=0.01 2/50 2/20 2/22 15/64 46/251 22/28 23/40 18/34 9/154 Control n/H 1/50 1/13 0/12 10/63 10/124 10/26 10/15 9/15 0/167 RR (95%CI fixed) Weight % 1.3 1.7 0.0 13.1 17.4 24.7 18.9 16.2 6.3 RR (95%CI fixed) 2.00(0.19,1.36) 1.00(0.10,10.04) 2.71(0.14,52.20) 1.40(0.72,2.04) 2.27(1.19,4.35) 1.10(0.82,1.56) 0.00(0.55,1.35) 0.00(0.52,1.49) 1.09(0.65,5.52) 100/670 64/450 100.0 1.38(1.07,1.72) 0.1 1 1 50 100 Favours control Favours epoetin Bohlius et al. Proc ASH 2003
Cervical cancer Phase III trial EPO beta 30 000 IU weekly Radiochemotherapy R n=74 Standard supportive care No significant differences - in time to progression or <strong>de</strong>ath (RR : 1,00 ; CI : 0,57– 0,57 1,75, p=0,99) - in overall survival (RR : 1,16 ; CI : 0,69–1,94 0,69 1,94 ; p=0,57) - or disease progression (RR : 1,08 ; CI : 0,62–1,87 0,62 1,87 ; p=0,79) From STRAUSS HG, abst 5121, ASCO 2005
Page 1:
FACTORES DE CRECIMIENTO HEMATOPOIET
Page 6 and 7:
FACTORES A CONSIDERAR EN LA PRESCRI
Page 12 and 13:
MAGNITUD DEL PROBLEMA: Estudio ECAS
Page 14 and 15:
ERITROPOYETINAS: Nivel Hb de inicio
Page 16 and 17:
ERITROPOYETINAS: Dosis Dosis Dosi
Page 18 and 19:
DOSIS ÓPTIMA: Relación dosis/peso
Page 20 and 21:
Corrección de la Anemia en RT Evol
Page 22 and 23:
► Expresión de EPO y de receptor
Page 24 and 25:
Expresión del Receptor de la Eritr
Page 26 and 27:
EPO-R en carcinoma de mama La tinc
Page 28 and 29:
Señalización EPO/EPO-R en la supe
Page 30 and 31: Ensayos “de alerta” con ARE BES
Page 34: Conclusiones: • No existen en la
Page 37 and 38: EPO-R en cáncer La expresión de E
Page 39 and 40: ¿Cómo interpretar los datos publi
Page 41 and 42: RECEPTORES DE EPO EN CÉLULAS TUMOR
Page 43: d o i : 1 0 . 1 0 3 8 / n m 1 2 0 3
Page 46 and 47: Anemia en el paciente oncológico I
Page 48 and 49: ¿ES ÚTIL LA EPO EN LA REDUCCIÓN
Page 52 and 53: CONCLUSIONES DEL ESTUDIO HCP (Casas
Page 54: Reduced transfusions in anaemic pat
Page 58: COMENTARIOS EORTC-GUIDELINES EORTC
Page 61 and 62: CONTROLLED MULTICENTRE STUDY OF THE
Page 63 and 64: BREAST CANCER TRIAL WITH EPO TERMIN
Page 67 and 68: EORTC Guidelines for the use of EPO
Page 69 and 70: EPO Y SUPERVIVENCIA No hay evidenci
Page 71 and 72: Outcomes of epoetin-treated epoetin
Page 73 and 74: CONCLUSIONES Seguridad y efectivid
Page 75 and 76: Survival with epoetin Studies incon
Page 77 and 78: “ The characteristics of the pati
Page 79: ENHANCE study results are inconsist
Page 83 and 84: High dose recombinant human erythro
Page 85 and 86: Estudio BEST: BEST: Análisis Poste
Page 87: Nature Medicine 9: 1439, 2003
show all

2008 - Factores de crecimiento hematopoyético-Dr. A. Biete - GICOR

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?